This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

ORESTE GALLO, MD; ANNA MARIA GORI; MONICA ATTANASIO; FRANCESCA MARTINI; GRAZIANI PAOLA, MD; OMERO FINI STORCHI, MD; ROSANNA ABBATE, MD
Florence, Italy

Arch Otolaryngol Head Neck Surg. 1992;118(12):1366.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—In a recent article published in the January issue of the ARCHIVES, Clayman et al¹ described the possible correlation among serum levels of acute-phase proteins and in vitro serum modulation of the lymphokine-activated killer cell induction phase and in vivo interleukin 2 (IL-2)-induced toxicity in patients with head and neck cancer who are receiving IL-2/interferon alfa immunotherapy. The authors, in agreement with others,² found elevated levels of such proteins in head and neck cancer patients before therapy was started and suggested the central role of IL-1 in the control of their production and its modulation by the recombinant cytokines used for therapy. In this article, however, the possible role of IL-6 in controlling liver production of acute-phase protein levels in the serum has not been taken into account. Interleukin 6 is a multifunctional cytokine with pleiotropic action that regulates the acute-phase response of the organism . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?